ClinicalTrials.gg
RecruitingNCT07853976UV-MEL-IMPLANTUpdated Oct 2, 2026

Clinical and Radiographic Evaluation of UV-Treated Dental Implants With or Without Melatonin in the Upper Posterior Jaw

An interventional study of UV-Photofunctionalized Dental Implant and Conventional Dental Implant in Jaw, Edentulous, Partially, Bone Resorption and Dental Implant Failure, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Feb 2026, registered Sep 2026).
  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate and compare the clinical and radiographic outcomes of using photofunctionalized (UV-treated) dental implants with or without the application of melatonin hormone in the posterior maxilla (upper back jaw).

The posterior maxilla is known to have lower bone quality, which can negatively affect the primary and secondary stability of dental implants,. UV photofunctionalization is a method that modifies the titanium surface of the implant, changing it from hydrophobic (water-repelling) to superhydrophilic (water-attracting). This enhancement aims to accelerate protein adsorption and promote bone-building cells (osteoblasts). On the other hand, melatonin acts as an anti-inflammatory and antioxidant agent that stimulates bone formation and reduces bone resorption.

A total of 21 dental implants will be placed in patients requiring tooth replacement in the posterior maxilla. The implants will be divided into three main approaches: one using UV-treated implants alone, and the other combining UV-treated implants with melatonin. and one using conventional implant Patients will be followed up clinically and radiographically to assess implant stability, bone healing, and overall implant success over time.

Read the detailed description

This interventional study is designed to clinically and radiographically evaluate the potential synergistic effects of ultraviolet (UV) photofunctionalized dental implants combined with melatonin hormone in the posterior maxilla, bone density (D4 bone quality) and challenging primary implant stability.

Biological aging of titanium is an unavoidable phenomenon occurring within weeks of manufacturing, where hydrocarbon contamination covers the protective titanium dioxide layer, increasing surface hydrophobicity and reducing optimal osteoblast adhesion. To counteract this, UV photofunctionalization (UV irradiation) will be utilized immediately prior to implant insertion to restore superhydrophilic properties, reduce hydrocarbon content, and enhance early protein adsorption and osteoblastic differentiation.

Additionally, melatonin (N-acetyl-5-methoxytryptamine) will be investigated as an alternative graft or bioactive material. Melatonin exhibits potent anti-inflammatory and antioxidant capabilities, destroys reactive oxygen species, and stimulates human osteoblasts to synthesize type I collagen fibers. It also down-regulates RANKL-mediated osteoclast activation, thereby reducing bone resorption during the critical early healing phases.

Patients will be selected from the Outpatient Clinic of the Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Mansoura University, following ethical committee approval and obtaining informed written consents. A total of 21 implants will be placed in the posterior maxilla. The clinical and radiographic evaluation will monitor parameters such as primary and secondary implant stability, marginal bone level changes, and peri-implant tissue health to compare the outcomes of photofunctionalized implants alone against those combined with melatonin.

02

Conditions studied

  • Jaw, Edentulous, Partially
  • Bone Resorption
  • Dental Implant Failure

Keywords

  • photofunctionalized Dental Implants
  • UV Treatment
  • Melatonin
  • Posterior Maxilla
  • Osseointegration
  • Implant Stability
03

In context

Jaw, Edentulous, Partially

76 studies on the registry are indexed under Jaw, Edentulous, Partially; 7 are open to participants now.

This study's planned enrollment of 21 is below the median of 38 across 67 interventional studies indexed under Jaw, Edentulous, Partially.

Browse Jaw, Edentulous, Partially studies →

Lead sponsor

Mansoura University is the lead sponsor of 1,121 studies on the registry; 183 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 60 years old.
  • Patients seeking replacement of missed single or multiple teeth in the posterior maxilla.
  • Sufficient bone volume (height and width) to accommodate dental implant placement without major bone grafting.
  • Good oral hygiene and motivated patients.
  • Systemically healthy patients with no for minor oral surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients with uncontrolled systemic diseases
  • Patients who received radiation therapy in the head and neck region within the last 5 years.
  • Heavy smokers (more than 10 cigarettes per day).
  • Patients with active periodontal disease or poor oral hygiene.
  • Pregnant or lactating females.
  • Parafunctional habits such as severe bruxism or clenching.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Experimental: UV-Implant + Melatonin

    Patients in this group will receive ultraviolet (UV) photofunctionalized dental implants combined with the topical application of melatonin hormone at the implant site in the posterior maxilla to evaluate early bone formation.

    Device: UV-Photofunctionalized Dental Implant

  • Active comparator
    Active Comparator: UV-Implant Alone

    Patients in this group will receive ultraviolet (UV) photofunctionalized dental implants alone without the application of melatonin hormone in the posterior maxilla to serve as the active control group.

    Device: UV-Photofunctionalized Dental Implant

  • Active comparator
    Conventional Dental Implant

    Patients in this group will receive conventional titanium dental implants in the posterior maxilla to serve as the baseline control group.

    Device: Conventional Dental Implant

Interventions

  • DeviceUV-Photofunctionalized Dental Implant

    Commercial titanium dental implants subjected to ultraviolet (UV) light irradiation immediately prior to surgical placement to convert the surface property from hydrophobic to superhydrophilic.

  • DeviceConventional Dental Implant

    Standard commercial titanium dental implants placed using traditional surgical protocols without any UV surface photofunctionalization or melatonin application.

06

What researchers measure

Primary outcomes

  1. Implant Stability (ISQ)

    Implant stability will be measured using Resonance Frequency Analysis (RFA) to obtain the Implant Stability Quotient (ISQ) value. Higher ISQ values indicate greater primary and secondary implant stability.

    Time frame: At the time of implant placement (baseline), 2, 4, weeks, 3 and 9 months

Secondary outcomes

  1. Marginal Bone Level Changes

    Radiographic evaluation using standardized digital periapical radiographs to measure peri-implant marginal bone loss or gain in millimeters.

    Time frame: At the time of implant placement (baseline), 3 months, and 9 months post-operatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Soler G, Bernal-Vicente A, Anton AI, Torregrosa JM, Caparros-Perez E, Sanchez-Serrano I, Martinez-Perez A, Sanchez-Vega B, Vicente V, Ferrer-Marin F. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. Ann Hematol. 2015 May;94(5):789-94. doi: 10.1007/s00277-014-2266-y. Epub 2014 Dec 9. PubMed 25482455 ↗
  • Lindquist SG, Braedgaard H, Svenstrup K, Isaacs AM, Nielsen JE; FReJA Consortium. Frontotemporal dementia linked to chromosome 3 (FTD-3)--current concepts and the detection of a previously unknown branch of the Danish FTD-3 family. Eur J Neurol. 2008 Jul;15(7):667-70. doi: 10.1111/j.1468-1331.2008.02144.x. Epub 2008 May 15. PubMed 18484988 ↗
  • Rocchigiani G, Ricci E, Navarro MA, Samol MA, Uzal FA. Leukocyte numbers and intestinal mucosal morphometrics in horses with no clinical intestinal disease. J Vet Diagn Invest. 2022 May;34(3):389-395. doi: 10.1177/10406387211031944. Epub 2021 Jul 23. PubMed 34293980 ↗
  • Tian X, Raina DB, Vater C, Kilian D, Ahlfeld T, Platzek I, Nimtschke U, Tagil M, Lidgren L, Thomas A, Platz U, Schaser KD, Disch AC, Zwingenberger S. Evaluation of an Injectable Biphasic Calcium Sulfate/Hydroxyapatite Cement for the Augmentation of Fenestrated Pedicle Screws in Osteoporotic Vertebrae: A Biomechanical Cadaver Study. J Funct Biomater. 2022 Dec 1;13(4):269. doi: 10.3390/jfb13040269. PubMed 36547529 ↗
  • Chen DW, Yu HH, Luo LJ, Rajesh Kumar S, Chen CH, Lin TY, Lai JY, Jessie Lue S. Osteoblast Biocompatibility and Antibacterial Effects Using 2-Methacryloyloxyethyl Phosphocholine-Grafted Stainless-Steel Composite for Implant Applications. Nanomaterials (Basel). 2019 Jun 28;9(7):939. doi: 10.3390/nano9070939. PubMed 31261737 ↗
  • Lang X, Qiao B, Ge Z, Yan J, Zhang Y. Clinical Effects of Photofunctionalization on Implant Stability and Marginal Bone Loss: Systematic Review and Meta-Analysis. J Clin Med. 2022 Nov 28;11(23):7042. doi: 10.3390/jcm11237042. PubMed 36498616 ↗
  • Lee D, Lee JS, Sezirahiga J, Kwon HC, Jang DS, Kang KS. Bioactive Phytochemicals Isolated from Akebia quinata Enhances Glucose-Stimulated Insulin Secretion by Inducing PDX-1. Plants (Basel). 2020 Aug 24;9(9):1087. doi: 10.3390/plants9091087. PubMed 32847055 ↗
  • Nganda B, Wang'ombe J, Floyd K, Kangangi J. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Machakos District, Kenya. Int J Tuberc Lung Dis. 2003 Sep;7(9 Suppl 1):S14-20. PubMed 12971650 ↗
  • Matsuo T, Mori N, Sakurai A, Furukawa K. Varicella-zoster virus myeloencephalitis. IDCases. 2017 Oct 20;10:110-111. doi: 10.1016/j.idcr.2017.10.006. eCollection 2017. No abstract available. PubMed 29124011 ↗
  • Coll AM, Ameen JR, Mead D. Postoperative pain assessment tools in day surgery: literature review. J Adv Nurs. 2004 Apr;46(2):124-33. doi: 10.1111/j.1365-2648.2003.02972.x. PubMed 15056325 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Of 34 interventional studies with no phase under Jaw, Edentulous, Partially, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 61. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartActual
Feb 21, 2026
Primary completionEst.
Nov 21, 2026
CompletionEst.
Nov 21, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853976
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Feb 21, 2026
Primary completion
Nov 21, 2026 (estimated)
Completion
Nov 21, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Ali K Ali, BDS
Contact
ak3605773@gmail.com
00201553005571

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion